Effects of travoprost on aqueous humor dynamics in patients with elevated intraocular pressure

Journal of Glaucoma

Volumn 16, Issue 2, 2007, Pages 189-195

  Toris, Carol B ^a,c   Zhan, Guilin ^a   Fan, Shan ^a   Dickerson, Jaime E ^b   Landry, Theresa A ^b   Bergamini, Michael V W ^b   Camras, Carl B ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b ALCON RESEARCH LTD   (United States)

^c 985840 Nebraska Medical Center ^*  (United States)

Author keywords

Aqueous humor dynamics; Glaucoma; Intraocular pressure; Prostaglandins; Travoprost

Indexed keywords

ADRENALIN; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; MIOTIC AGENT; PLACEBO; PROSTAGLANDIN; TRAVOPROST;

ADULT; AGED; ANAMNESIS; AQUEOUS HUMOR FLOW; ARTICLE; BODY POSITION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; FEMALE; FLUOROPHOTOMETRY; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; MANOMETRY; MATHEMATICAL ANALYSIS; MEASUREMENT; OCULOPLETHYSMOGRAPHY; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; STUDENT T TEST; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; AQUEOUS HUMOR; CLOPROSTENOL; DOUBLE-BLIND METHOD; FEMALE; FLUOROPHOTOMETRY; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; TONOMETRY, OCULAR;

EID: 34247644962     PISSN: 10570829     EISSN: None     Source Type: Journal    
DOI: 10.1097/IJG.0b013e31802fc6d3     Document Type: Article

References (71)

1. Hellberg MR, Sallee VL, McLaughlin MA, et al. Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist. J Ocul Pharmacol Ther. 2001;17:421-432.
2. Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132:472-484.
3. Goldberg I, Cunha-Vaz J, Jakobsen J-E, et al. Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. J Glaucoma. 2001;10:414-422.
4. Hellberg MR, McLaughlin MA, Sharif NA, et al. Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonist. Surv Ophthalmol. 2002;47:S13-S33.
5. Parrish RK, Palmberg P, Sheu W-P, for the XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003;135:688-703.
6. Fellman RL, Sullivan EK, Ratliff M, et al. Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial. Ophthalmology. 2002;109:998-1008.
7. Toris CB, Zhan G-L, Camras CB, et al. Effects of travoprost on aqueous humor dynamics in monkeys. J Glaucoma. 2005;14:70-73.
8. 2a analog, on aqueous humor dynamics in human eyes. Ophthalmology. 1993;100:1297-1304.
9. 2a analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol. 1993;111:1351-1358.
10. Toris CB, Camras CB, Yablonski ME, et al. Effects of exogenous prostaglandins on aqueous humor dynamics and blood-aqueous barrier function. Surv Ophthalmol. 1997;41:S69-S75.
11. Weinreb RN, Toris CB, Gabelt BT, et al. Effects of prostaglandins on the aqueous humor outflow pathways. Surv Ophthalmol. 2002;47:S53-S64.
12. Mastropasqua L, Carpineto P, Ciancaglini M, et al. A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma. Ophthalmology. 1999;106:550-555.
13. Brubaker RF, Schoff EO, Nau CB, et al. Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Am J Ophthalmol. 2001;131:19-24.
14. Toris CB, Zhan G, Camras CB. Increase in outflow facility with unoprostone treatment in ocular hypertensive patients. Arch Ophthalmol. 2004;122:1782-1787.
15. Christiansen GA, Nau CB, McLaren JW, et al. Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma. Ophthalmology. 2004;111:1658-1662.
16. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701-713.
17. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:714-720.
18. Hayreh SS, Zimmerman MB, Podhajsky P, et al. Nocturnal arterial hypotension and its role in optic nerve head and ocular ischemic disorders. Am J Ophthalmol. 1994;117:603-624.
19. Liu JHK, Kripke DF, Hoffman RE, et al. Nocturnal elevation of intraocular pressure in young adults. Invest Ophthalmol Vis Sci. 1998;39:2707-2712.
20. Liu JHK, Kripke DF, Hoffman RE, et al. Elevation of human intraocular pressure at night under moderate illumination. Invest Ophthalmol Vis Sci. 1999;40:2439-2442.
21. Liu JHK, Kripke DF, Twa MD, et al. Twenty-four-hour pattern of intraocular pressure in the aging population. Invest Ophthalmol Vis Sci. 1999;40:2912-2917.
22. Weinreb RN, Liu JH. Nocturnal rhythms of intraocular pressure. Arch Ophthalmol. 2006;124:269-270.
23. Topper JE, Brubaker RF. Effects of timolol, epinephrine, and acetazolamide on aqueous flow during sleep. Invest Ophthalmol Vis Sci. 1985;26:1315-1319.
24. Brubaker RF. Flow of aqueous humor in humans. Invest Ophthalmol Vis Sci. 1991;32:3145-3166.
25. Rácz P, Ruzsonyi MR, Nagy ZT, et al. Around-the-clock intraocular pressure reduction with once-daily application of latanoprost by itself or in combination with timolol. Arch Ophthalmol. 1996;114:268-273.
26. Dubiner HB, Sircy MD, Landry T, et al. Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure. Clin Ther. 2004;26:84-91.
27. Walters TR, Dubiner HB, Carpenter SP, et al, for the Bimatoprost Circadian IOP Study Group. 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial. Surv Ophthalmol. 2004;49:S26-S35.
28. Mishima HK, Kiuchi Y, Takamatsu M, et al. Circadian intraocular pressure management with latanoprost: diurnal and nocturnal intraocular pressure reduction and increased uveoscleral outflow. Surv Ophthalmol. 1997;41:S139-S144.
29. Larsson L-I. Intraocular pressure over 24 hours after repeated administration of latanoprost 0.005% or timolol gel-forming solution 0.5% in patients with ocular hypertension. Ophthalmology. 2001;108:1439-1444.
30. Larsson L-I, Mishima HK, Takamatsu M, et al. The effect of latanoprost on circadian intraocular pressure. Surv Ophthalmol. 2002;47:S90-S96.
31. Orzalesi N, Rossetti L, Invernizzi T, et al. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci. 2000;41:2566-2573.
32. Carlson KH, Bourne WM, McLaren JW, et al. Variations in human corneal endothelial cell morphology and permeability to fluorescein with age. Exp Eye Res. 1988;47:27-41.
33. Schenker HI, Yablonski ME, Podos SM, et al. Fluorophotometric study of epinephrine and timolol in human subjects. Arch Ophthalmol. 1981;99:1212-1216.
34. Yablonski ME, Zimmerman TJ, Waltman SR, et al. A fluorophotometric study of the effect of topical timolol on aqueous humor dynamics. Exp Eye Res. 1978;27:135-142.
35. Zeimer RC, Gieser DK, Wilensky JT, et al. A practical venomanometer. Measurement of episcleral venous pressure and assessment of the normal range. Arch Ophthalmol. 1983;101:1447-1449.
36. Hayashi M, Yablonski ME, Novack GD. Trabecular outflow facility determined by fluorophotometry in human subjects. Exp Eye Res. 1989;48:621-625.
37. Brubaker RF, Nagataki S, Bourne WM. Effect of chronically administered timolol on aqueous humor flow in patients with glaucoma. Ophthalmology. 1982;89:280-283.
38. Dailey BA, Brubaker RF, Bourne WM. The effects of timolol maleate and acetazolamide on the rate of aqueous formation in normal human subjects. Am J Ophthalmol. 1982;93:232-237.
39. McCannel CA, Heinrich SR, Brubaker RF. Acetazolamide but not timolol lowers aqueous humor flow in sleeping humans. Graefes Arch Clin Exp Ophthalmol. 1992;230:518-520.
40. Kupfer C, Gaasterland D, Ross K. Studies of aqueous humor dynamics in man. II. Measurements in young normal subjects using acetazolamide and L-epinephrine. Invest Ophthalmol. 1971;10:523-533.
41. Kupfer C, Gaasterland D, Ross K. Studies of aqueous humor dynamics in man. V. Effects of acetazolamide and isoproterenol in young and old normal volunteers. Invest Ophthalmol. 1976;15:349-355.
42. Larsson L-I, Alm A. Aqueous humor flow in human eyes treated with dorzolamide and different doses of acetazolamide. Arch Ophthalmol. 1998;116:19-24.
43. Lauber JK, Frankelson EN, Boyd TAS. Influence of Diamox (acetazolamide) on aqueous flow. Can J Ophthalmol. 1972;7:341-348.
44. Maus TL, Larsson L-I, McLaren JW, et al. Comparison of dorzolamide and acetazolamide as suppressors of aqueous humor flow in humans. Arch Ophthalmol. 1997;115:45-49.
45. Toris CB, Zhan G-L, Yablonski ME, et al. Effects on aqueous flow of dorzolamide combined with either timolol or acetazolamide. J Glaucoma. 2004;13:210-215.
46. Konstas AGP, Mikropoulos D, Kaltsos K, et al. Twenty-four-hour intraocular pressure control obtained with evening- versus morning-dosed travoprost in primary open-angle glaucoma. Ophthalmology. 2006;113:446-450.
47. Orzalesi N, Rossetti L, Bottoli A, et al. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Ophthalmology. 2006;113:239-246.
48. Sit AJ, Weinreb RM, Crowston JG, et al. Sustained effect of travoprost on diurnal and nocturnal intraocular pressure. Am J Ophthalmol. 2006;141:1131-1133.
49. Henkind P, Leitman M, Weitzman E. The diurnal curve in man: new observations. Invest Ophthalmol. 1973;12:705-707.
50. Kitazawa Y, Horie T. Diurnal variation of intraocular pressure in primary open-angle glaucoma. Am J Ophthalmol. 1975;79:557-566.
51. Weitzman ED, Henkind P, Leitman M, et al. Correlative 24-hour relationships between intraocular pressure and plasma cortisol in normal subjects and patients with glaucoma. Br J Ophthalmol. 1975;59:566-572.
52. Weinreb RN, Polansky JR, Kramer SG, et al. Acute effects of dexamethasone on intraocular pressure in glaucoma. Invest Ophthalmol Vis Sci. 1985;26:170-175.
53. Ido T, Tomita G, Kitazawa Y. Diurnal variation of intraocular pressure of normal-tension glaucoma. Influence of sleep and arousal. Ophthalmology. 1991;98:296-300.
54. Kothe AC. The effect of posture on intraocular pressure and pulsatile ocular blood flow in normal and glaucomatous eyes. Surv Ophthalmol. 1994;38:S191-S197.
55. Brubaker RF. Mechanism of action of bimatoprost (Lumigan™). Surv Ophthalmol. 2001;45:S347-S351.
56. 2α receptors in the human trabecular meshwork. Invest Ophthalmol Vis Sci. 1998;39:315-321.
57. Wiederholt M, Thieme H, Stumpff F. The regulation of trabecular meshwork and ciliary muscle contractility. Prog Retin Eye Res. 2000;19:271-295.
58. Krauss AHP, Wiederholt M, Sturm A, et al. Prostaglandin effects on the contractility of bovine trabecular meshwork and ciliary muscle. Exp Eye Res. 1997;64:447-453.
59. Toris CB, Zhan G-L, Zhao J, et al. Potential mechanism for the additivity of pilocarpine and latanoprost. Am J Ophthalmol. 2001;131:722-728.
60. Sakurai M, Araie M, Oshika T, et al. Effects of topical application of UF-021, a novel prostaglandin derivative, on aqueous humor dynamics in normal human eyes. Jpn J Ophthalmol. 1991;35:156-165.
61. Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. Exp Eye Res. 1998;67:179-191.
62. Toris CB, Koepsell SA, Yablonski ME, et al. Aqueous humor dynamics in ocular hypertensive patients. J Glaucoma. 2002;11:253-258.
63. Toris CB, Zhan G-L, Wang Y-L, et al. Aqueous humor dynamics in monkeys with laser-induced glaucoma. J Ocul Pharmacol Ther. 2000;16:19-27.
64. 2 increases uveoscleral outflow and trabecular outflow facility in the cat. Exp Eye Res. 1995;61:649-657.
65. 2α on aqueous humor dynamics in cynomolgus monkeys. Curr Eye Res. 1987;6:1035-1044.
66. Kaufman PL, Crawford KS. Aqueous humor dynamics: how PGF2a lowers intraocular pressure. In: Bito LZ, Stjernschantz J, eds. The Ocular Effects of Prostaglandins and Other Eicosanoids. Vol. 312. New York: Alan R. Liss, Inc.; 1989:387-416.
67. Bill A. Some thoughts on the pressure dependence of uveoscleral flow. J Glaucoma. 2003;12:88-89.
68. Camras CB. Some thoughts on the pressure dependence of uveoscleral flow. J Glaucoma. 2003;12:92-93.
69. Yablonski ME. Some thoughts on the pressure dependence of uveoscleral flow. J Glaucoma. 2003;12:90-92.
70. Kaufman PL. Some thoughts on the pressure dependence of uveoscleral flow. J Glaucoma. 2003;12:89.
71. Reiss GR, Lee DA, Topper JE, et al. Aqueous humor flow during sleep. Invest Ophthalmol Vis Sci. 1984;25:776-778.